We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
130-LB: Retrospective Evaluation of Treatment Patterns in a Real-Life Setting Environment with Dapagliflozin or DPP-4 Inhibitors as Add-On Therapy in Uncontrolled DM2 Patients Who Previously Failed on Other Regimens.
- Authors
ESPINOZA-PERALTA SR., DIEGO; GONZÁLEZ-CANTÚ, ARNULFO; SILVA II, ALEJANDRA I.; COLLADO, JUAN G.; ROGEL-MANZANARES, JORGE DAVID; HERNÁNDEZ-ALARCÓN, JIMENA H.; NORIEGA-MUÑOZ, ANA G.
- Abstract
Mexico is one of LatinAmerica countries with the highest prevalence (14.4%) of DM. Medical institutions face the challenge to provide medical care to T2DM patients that failed to several antidiabetic regimens. We conducted a retrospective study to assess the response to dapagliflozin (Dapa) or DPP-4-inhibitors (DPP-4i) as added-on therapy in T2DM patients with failure to previous medications. Objectives: Compare subjects with ≥5% improvement of the weighted sum of the three variables of the composite variable (HbA1c plus body weight (BW) plus blood pressure (BP) by the end of the 74-week observation period from index date) and proportion of patient achieving HBA1c of 7%. Inclusion Criteria: T2DM subjects ≥18 years old with failure to any previous antidiabetic medication and HbA1c% ≥7 that started Dapa or DPP-4i as add-on to other antidiabetic drugs from August 2014 to Jun 2018. Statistical Methods and Analysis: A propensity score matching model (nearest neighbor algorithm) was used, covariates included were treatment regimen, TC, LDL-c, HbA1c, BW, systolic BP and age. Results: Of 1800 subjects, 221 met statistical matching criteria. No differences in basal characteristics of age, SBP, CrCl, but DAPA group had higher basal HbA1c (8.68±1.59 vs. 8.19±1.4, p<0.01). Dapa group had a significant improvement (>5%) in the composite variable compared to DPP-4i at 24 (76.9% vs. 46%, p<0.01), 52 (82.4% vs. 49.5%, p<0.01) and 76 weeks(84.6% vs. 39.2%, p<0.01). Patients with HbA1c goal of <7% in Dapa group compared to iDPP-4 at 24 (44.3% vs. 29.9%, p<0.01), 52 (48.9% vs. 29.1%, p<0.01) and 76 weeks (51.9% vs. 21.8%, p<0.01). Conclusion: In patients with uncontrolled T2DM who have failed to previous antidiabetic therapies, the add-on of dapagliflozin significantly provides reductions of HbA1c, glucose, weight and blood with more patients achieving glucose control goals compared to iDPP-4. Disclosure: D. Espinoza-Peralta: None. A. González-Cantú: None. A.I. Silva: Employee; Self; AstraZeneca. J.G. Collado: None. J. Rogel-Manzanares: None. J.H. Hernández-Alarcón: None. A.G. Noriega-Muñoz: None.
- Publication
Diabetes, 2020, Vol 69, pN.PAG
- ISSN
0012-1797
- Publication type
Article
- DOI
10.2337/db20-130-LB